Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04880031
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2021-05-05
Brief Title:
A Study of BOS-580 in Obese Subjects At Risk For or with Biopsy-confirmed Nonalcoholic Steatohepatitis NASH with an Extension
Sponsor:
Boston Pharmaceuticals
Organization:
Boston Pharmaceuticals
Study Overview
Official Title:
A Phase 2a Randomized Blinded Placebo-controlled Study of BOS-580 in Obese Subjects At Risk For or with Biopsy-confirmed Nonalcoholic Steatohepatitis NASH with a Single Arm Open-label Extension
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized blinded placebo-controlled study of BOS-580 in obese participants at risk for or with biopsy-confirmed nonalcoholic steatohepatitis NASH with a single arm open-label extension It includes Parts A B C and D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None